Sciegen Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SCIEGEN PHARMS INC, and what generic and branded alternatives to SCIEGEN PHARMS INC drugs are available?
SCIEGEN PHARMS INC has sixty-three approved drugs.
Drugs and US Patents for Sciegen Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sciegen Pharms Inc | PREGABALIN | pregabalin | TABLET, EXTENDED RELEASE;ORAL | 215675-003 | Sep 14, 2022 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Sciegen Pharms Inc | FLUOXETINE HYDROCHLORIDE | fluoxetine hydrochloride | TABLET;ORAL | 211282-001 | Jan 10, 2019 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sciegen Pharms Inc | PRAMIPEXOLE DIHYDROCHLORIDE | pramipexole dihydrochloride | TABLET;ORAL | 203855-001 | Oct 28, 2014 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sciegen Pharms Inc | RANOLAZINE | ranolazine | TABLET, EXTENDED RELEASE;ORAL | 211829-002 | Jun 4, 2019 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sciegen Pharms Inc | NAPROXEN | naproxen | TABLET;ORAL | 212517-003 | Feb 21, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sciegen Pharms Inc | LACOSAMIDE | lacosamide | TABLET;ORAL | 205237-004 | Mar 17, 2022 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.